Please select the option that best describes you:

Is there value to OncoType Dx and/or NGS testing for mutations such as ESR1 in patients who have ipsilateral isolated resectable skin recurrence in ER+ positive low Oncotype breast cancer 10 years after mastectomy and adjuvant AI for 5 years?  

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Providence Hospital and Medical Centers
Thank you, Dr. @Soliman. That is very helpful.
Sign in or Register to read more